Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | HPGD | P15428 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | HPGDS | O60760 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848880 | 1.00 | ALDH1A1 (0.74) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2844957 | 0.96 | MEN1 (0.74) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2844952 | 0.96 | MEN1 (0.74) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2846679 | 0.91 | ALDH1A1 (0.76) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2846684 | 0.91 | ALDH1A1 (0.76) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2848903 | 0.91 | MEN1 (0.71) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2848905 | 0.91 | MEN1 (0.71) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL16215157 | 0.90 | ALDH1A1 (0.59) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL15396767 | 0.90 | TRPA1 (0.61) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL15396856 | 0.90 | TRPA1 (0.63) | ALDH1A1HPGDMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2023-02-21 | — | — | US | disclosed |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2020-09-29 | — | — | US | disclosed |
| US-10695353-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2020-06-30 | — | — | US | disclosed |
| EP-3485883-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OccuRx Pty Ltd (AU) | 2019-05-22 | — | — | EP | disclosed |
| EP-2642989-B1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2019-01-02 | — | — | EP | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| EP-2035369-B1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-06-25 | — | — | EP | disclosed |
| EP-2035369-B1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-06-25 | — | — | EP | disclosed |
| WO-2012068612-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-05-31 | — | — | WO | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| WO-2008131481-A1 | TREATMENT OF MESANGIOPROLIFERATIVE DISEASES | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-10695353-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | ALDH1A1 199/4885HPGD 536/4885MEN1 2640/4885 |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.